BD

Balakrishnan Dananjayan

Active Director Director DIN 06416843
DIN 06416843 First appointment Nov 2012 Primary industry Business Outsourcing
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Balakrishnan Dananjayan

Data last updated:

Balakrishnan Dananjayan is a Director at Bvm Pharma Limited (since 2012). The company operates in Business Outsourcing.

DIN 06416843
Primary Designation Director
Industry Business Outsourcing
First Appointment 09 Nov 2012
Oldest Company Age 13 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Bvm Pharma Limited U74120UP2012PLC053599
Director09 Nov 20122012Active

Board colleagues of Balakrishnan Dananjayan

NameDINCompanyDesignation
Amit Kumar Singh00996528Bvm Pharma LimitedAdditional Director
Omvir Singh05142844Bvm Pharma LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Bvm Pharma Limited
Premium access

Shareholding and investment profile for Balakrishnan Dananjayan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Balakrishnan Dananjayan

Balakrishnan Dananjayan currently holds 1 directorship: Bvm Pharma Limited (Director, since 09 Nov 2012).

Balakrishnan Dananjayan was first appointed on 09 Nov 2012 as Director at Bvm Pharma Limited.

The current boards of Balakrishnan Dananjayan's companies include Amit Kumar Singh (Bvm Pharma Limited), Omvir Singh (Bvm Pharma Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available